IRS 280E Loophole Closes for Medical Marijuana After Schedule Shift
A tax code change triggered by marijuana's rescheduling removes Section 280E burdens for medical operators.
Why it matters: Legal professionals advising cannabis businesses must understand the end of 280E's stifling tax regime. This regulatory shift transforms cash flow, compliance, and financial planning for state-licensed medical marijuana operators.
- Section 280E of the tax code disallowed standard deductions for Schedule I/II drug businesses, impacting cannabis firms.
- Trump’s Executive Order 14370 (Dec. 2025) led DOJ to reclassify certain marijuana products as Schedule III.
- The April 2026 DOJ order excludes FDA-approved, state-licensed medical marijuana from 280E, unlocking potential $2.3B annual tax savings.
- Treasury and IRS will issue tax guidance to clarify post-rescheduling compliance, with adult-use marijuana still excluded.
A little-known sentence in the Internal Revenue Code, Section 280E, has dictated the tax fate of cannabis businesses for decades. Previously, 280E disallowed deductions for businesses trafficking in Schedule I or II substances—forcing effective tax rates as high as 70% and undermining profitability in the sector (Wiss).
- On December 18, 2025, President Trump signed Executive Order 14370, directing expedited rescheduling of marijuana (Goodwin Law).
- By April 23, 2026, the Department of Justice issued its Final Order, reclassifying FDA-approved and state-licensed medical marijuana as Schedule III, effective immediately (Treasury).
- This move removes these products from the reach of Section 280E, allowing routine business deductions—transforming cannabis operators’ cash flows, balance sheets, and investor prospects almost overnight.
"The most commercially meaningful component is the treatment of Section 280E," noted Terry Mendez, CEO of Safe Harbor Financial. "For qualifying state-licensed medical operators, the order removes the disallowance of standard business deductions… effective federal tax rates as high as 70 percent or more [are] materially constraining cash flow."
For legal professionals, the change means the industry's business planning, valuations, and tax compliance requirements demand urgent reassessment. Treasury and IRS are working on new guidance to clarify transition rules for eligible businesses (Treasury).
- Rescheduling currently applies only to FDA-approved, state-licensed medical marijuana—adult-use remains Schedule I and subject to 280E (mg Magazine).
This is widely viewed as a true inflection point for U.S. cannabis. As Karan Wadhera of Casa Verde Capital said: "Rescheduling unlocks the removal of 280E, fundamentally reshaping cash flows, balance sheets, and valuation frameworks overnight."
By the numbers:
- $2.3 billion — estimated annual federal tax savings to cannabis industry post-rescheduling
- 70% — potential effective federal tax rates under Section 280E before removal
- December 18, 2025 — date of Executive Order 14370 initiating rescheduling
Yes, but: The new tax treatment currently excludes adult-use (recreational) marijuana businesses, which remain subject to 280E’s penalties.
What's next: IRS and Treasury guidance is pending on the technical details of transitioning eligible businesses out of Section 280E rules.